Type of Assessment:
Comprehensive epithelial biomarker analysis of malignant mesothelioma: EpCAM positivity is a potential diagnostic pitfall
Cancer Cytopathology 2023 April 17 [Link] Yili Zhu, Simone Moore, Aihui Wang, Elizabeth George, Grace M Allard, Diane M Libert, Alarice C Lowe Abstract Background: Epithelial cell adhesion molecule (EpCAM) is frequently used to distinguish carcinoma from background mesothelial cells during cytologic examination of body cavity fluids. Previously, the authors identified one malignant mesothelioma case…
Read MoreAntitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo
Biology Direct 2023 April 17 [Link] Monica Benvenuto, Valentina Angiolini, Chiara Focaccetti, Daniela Nardozi, Camilla Palumbo, Raffaele Carrano, Alessandra Rufini, Riccardo Bei, Martino Tony Miele, Patrizia Mancini, Giovanni Barillari, Mara Cirone, Elisabetta Ferretti, Grazia Raffaella Tundo, Luciano Mutti, Laura Masuelli, Roberto Bei Abstract Background: Malignant mesothelioma (MM) is a rare tumor with a dismal prognosis.…
Read MorePhase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Journal of Clinical Oncology 2023 April 20 [Link] Nicholas J Vogelzang, James J Rusthoven, James Symanowski, Claude Denham, E Kaukel, Pierre Ruffie, Ulrich Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold, Clet Niyikiza, Paolo Paoletti Abstract Purpose: Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months,…
Read MoreEpidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database
Cancer Medicine 2023 April 16 [Link] Patrick Bou-Samra, Austin Chang, Feredun Azari, Gregory Kennedy, Alix Segil, Emily Guo, Melina Marmarelis, Corey Langer, Sunil Singhal Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer of the cells lining the pleural cavity with a low overall incidence. The National Cancer Database (NCDB) released in August 2022…
Read MoreKRAS Mutations Are Associated with Shortened Survival in Patients with Epithelioid Malignant Pleural Mesothelioma
Cancers 2023 March 30 [Link] Margherita Vannucchi, Veronica Pennati, Clelia Mencaroni, Chiara Defraia, Ledi Bardhi, Francesca Castiglione, Cristiana Bellan, Camilla Eva Comin Abstract Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural surface that includes three major histologic subtypes, epitheliod, sarcomatoid and biphasic. Epithelioid mesothelioma is usually associated with better prognosis. The genetic…
Read MoreOne Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
International Journal of Molecular Sciences 2023 March 28 [Link] Thomas Hager, Sabrina Borchert, Michael Wessolly, Alexander Mathilakathu, Elena Mairinger, Jens Kollmeier, Thomas Mairinger, Balazs Hegedus, Kristina Greimelmaier, Jeremias Wohlschlaeger, Ken Herrmann, Fabian Dominik Mairinger Abstract Malignant pleural mesothelioma (MPM) is a mainly asbestos-related tumour associated with a very poor prognosis. Therapeutic approaches include multimodal therapy…
Read MoreA Selective ALDH1A3 Inhibitor Impairs Mesothelioma 3-D Multicellular Spheroid Growth and Neutrophil Recruitment
International Journal of Molecular Science 2023 April 3 [Link] Sara Boumya, Silvia Fallarini, Sonia Siragusa, Giovanni Petrarolo, Silvio Aprile, Valentina Audrito, Concettina La Motta, Silvia Garavaglia, Laura Moro, Giulia Pinton Abstract Aldehyde dehydrogenase 1A3 (ALDH1A3), one of the three members of the aldehyde dehydrogenase 1A subfamily, has been associated with increased progression and drug resistance…
Read MoreImmunotherapy vs. Chemotherapy in Subsequent Treatment of Malignant Pleural Mesothelioma: Which Is Better?
Journal of Clinical Medicine 2023 March 27 [Link] Xiaotong Guo, Lede Lin, Jiang Zhu Abstract (1) Background: Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor arising from the pleural surface. For relapsed MPM, there is no accepted standard of- are for subsequent treatment. Thus, we aimed to compare the efficacy of chemotherapy, targeting…
Read MoreSurgical phenotype of patients with peritoneal mesothelioma and a germline mutation
Cancer 2023 April 12 [Link] Yaniv Berger, Meghana Gadiraju, Ankit Dhiman, Katie Gilliam, Buerkley Opalecky, Heather Chen, Maria Helgeson, Oliver S Eng, Aliya N Husain, Michael W Drazer, Hedy L Kindler, Jane E Churpek, Kiran K Turaga Abstract Background: This study aimed to investigate if peritoneal mesothelioma (PM) patients with germline mutations (GM) have distinct…
Read MoreHigh mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma
Histopathology 2023 April 11 [Link] Gerard J Chu, Anthony Linton, Steven Kao, Sonja Klebe, Stephen Adelstein, Dannel Yeo, John E J Rasko , Wendy A Cooper Abstract Aims: Mesothelin (MSLN) is a cancer-associated antigen that is overexpressed in malignancies such as mesothelioma, pancreatic and ovarian cancer. It is also a target for novel personalised therapies,…
Read More